Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-336-0444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions
What is Milestone Pharmaceuticals' stock symbol?
Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."
How were Milestone Pharmaceuticals' earnings last quarter?
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($1.04) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.57. View Milestone Pharmaceuticals' Earnings History.
When is Milestone Pharmaceuticals' next earnings date?
What price target have analysts set for MIST?
5 brokerages have issued 12 month price objectives for Milestone Pharmaceuticals' shares. Their predictions range from $26.50 to $32.00. On average, they anticipate Milestone Pharmaceuticals' stock price to reach $30.10 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price. View Analyst Price Targets for Milestone Pharmaceuticals.
What is the consensus analysts' recommendation for Milestone Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Milestone Pharmaceuticals.
Has Milestone Pharmaceuticals been receiving favorable news coverage?
News stories about MIST stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Milestone Pharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Milestone Pharmaceuticals.
Are investors shorting Milestone Pharmaceuticals?
Milestone Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 15,200 shares, a decline of 19.1% from the August 30th total of 18,800 shares. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.1% of the shares of the stock are sold short. View Milestone Pharmaceuticals' Current Options Chain.
Who are some of Milestone Pharmaceuticals' key competitors?
Some companies that are related to Milestone Pharmaceuticals include Corcept Therapeutics (CORT), Uniqure (QURE), Pacira Biosciences (PCRX), Alder Biopharmaceuticals (ALDR), Insmed (INSM), Aimmune Therapeutics (AIMT), Tricida (TCDA), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK) and BELLUS Health (BLUSF).
What other stocks do shareholders of Milestone Pharmaceuticals own?
Who are Milestone Pharmaceuticals' key executives?
Milestone Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
- Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
- Mr. Timothy L. Maness, VP of Fin. (Age 59)
- Dr. Francis Plat, Chief Medical Officer (Age 61)
- Mr. Lorenz Muller, Chief Commercial Officer (Age 55)
When did Milestone Pharmaceuticals IPO?
(MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
When does the company's lock-up period expire?
Milestone Pharmaceuticals' lock-up period expires on Tuesday, November 5th. Milestone Pharmaceuticals had issued 5,500,000 shares in its public offering on May 9th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
How do I buy shares of Milestone Pharmaceuticals?
Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Milestone Pharmaceuticals' stock price today?
One share of MIST stock can currently be purchased for approximately $18.35.
How big of a company is Milestone Pharmaceuticals?
What is Milestone Pharmaceuticals' official website?
How can I contact Milestone Pharmaceuticals?
Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]
MarketBeat Community Rating for Milestone Pharmaceuticals (NASDAQ MIST)
MarketBeat's community ratings are surveys of what our community members think about Milestone Pharmaceuticals and other stocks. Vote "Outperform" if you believe MIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MIST will underperform the S&P 500 over the long term. You may vote once every thirty days.
